Organix ORGANIX Supplement Manufacturing

80% cartons, 20% jars: the packaging decisions that move your launch date

Packaging is a cost, a timeline risk and a shelf decision, usually decided last and usually the reason a launch slips. Primary versus secondary, moisture barriers, artwork, and the Egyptian label rule that changes artwork planning.

Across this factory's output, roughly 80% of what leaves is in carton boxes and 20% in jars. That ratio is a reasonable map of the market: cartons holding blisters, bottles or sachets are the default, and jars belong to the powder and sports-nutrition end of the category.

It is also the only part of packaging most brand owners think about — the shape of the thing on the shelf. The other three things packaging is to a manufacturer are a cost line, a protection specification and a scheduling problem. The last of those is why packaging sourcing is one of the stages that genuinely delays launches, and it does so in a specific, avoidable way: it is almost always started too late, because it is treated as a design task that can wait for the product to be finished.

It cannot. Primary packaging is a formulation decision.

Three layers, three different conversations

Primary packaging touches the product. Blister films and aluminium lidding, aluminium cold-form blister, HDPE bottles with induction seals, sachet and stick-pack laminates, glass or PET bottles, jars and their liners, aluminium tubes.

Secondary packaging is the carton, the label, the leaflet, the shrink or sleeve. This is where brand design lives and where regulatory text has to fit.

Tertiary packaging is the shipper, the case count and the pallet pattern. Nobody designs it and everybody pays for it. A carton four millimetres wider than it needed to be can cost you a layer per pallet, permanently, on every shipment you ever make.

The split that matters: secondary and tertiary are commercial decisions. Primary is a technical one, and it belongs in the first R&D conversation alongside the formula — not after it.

Moisture is most of the engineering

Ask a formulator what the primary pack is for and the answer is rarely "branding". It is usually water.

Effervescents are the extreme case. An effervescent tablet is an acid and a carbonate waiting for moisture, and ambient humidity is enough to start the reaction. That is why effervescent production needs low-humidity rooms — the capability is a plant-engineering project, not a machine purchase — and why the pack is non-negotiable: an aluminium tube with a desiccant stopper, or individual aluminium strip or cold-form sealing. Never a jar. Never a plain PVC blister. Our own effervescent department is recent, and the humidity engineering was the hard part of building it.

Hygroscopic powders are the common case: collagen, creatine, several amino acids, magnesium salts, extracts with high residual sugars, probiotics. For live cultures, water activity matters more than temperature does.

A rough barrier hierarchy, worst to best, for solids:

PackBarrierTypical use
Screw-cap jar, no sealWeakestBulk powders with low sensitivity
Jar or bottle with induction sealModerateTablets, capsules, powders
Bottle, induction seal plus desiccantGoodMoisture-sensitive solids
PVC blister with aluminium liddingModerateStandard tablets and capsules
Coated PVC or PVDC blisterGoodMild to moderate sensitivity
Aluminium cold-form blisterStrongestHigh sensitivity, effervescents
Aluminium laminate sachet or stickStrongestPowders, liquids, semi-solids

Oxygen and light are the second and third problems. Oils and oil-filled softgels want low oxygen and dark packaging; nitrogen flushing and oxygen scavengers exist for a reason; amber glass is not a styling choice.

One planning consequence that catches almost everyone: stability data belongs to the product in its pack. A shelf-life claim supported by a study run in an aluminium sachet does not transfer to a jar. Change the pack after the study and you are selling a product whose data describes something else.

Artwork is where the weeks actually go

Artwork feels like the fast part because designers work fast. The design is not the bottleneck. The content is.

A supplement pack has to carry the product name and dosage form, the ingredient list with quantities per dose, directions, net content, batch number and manufacture and expiry dates, storage conditions, country of origin, allergen declarations, the registration or notification reference, importer details for each destination market, and the name and address of the manufacturing facility.

That last item is law in Egypt, and it reshapes artwork planning in four ways people do not anticipate:

  1. Artwork cannot be finalised before the factory is chosen. The two tasks are usually assumed to run in parallel. They cannot. The commercial side of that rule is covered in your factory's name goes on your label.
  2. The layout has to reserve real, legible space for it. Not a 4pt line squeezed into a side panel after the design is approved.
  3. Switching factory means reprinting. Your pack acquires a switching cost the day it goes to press.
  4. Multi-market packs carry the Egyptian requirement plus each destination's. Those requirements do not always want the same information in the same place.

Two further artwork traps, both cheap to avoid and expensive to discover:

Leave a clean coding area. Batch and expiry are overprinted at the factory. Designers routinely place a photograph or a gradient exactly where the coder has to print, and the result is a batch number nobody can read — which is a traceability failure, not a cosmetic one.

Own your barcodes and respect their quiet zones. The GTIN should be yours, not your factory's. An unreadable barcode is a retailer rejection, and it is discovered at the retailer.

The cost structure, honestly

For low-dose products in premium cartons, packaging can approach or exceed the cost of the formula inside it. The drivers, in rough order of impact:

  • Order quantity. Printers and converters have minimums, and their minimum is usually larger than your first production run. You will either buy more cartons than you need or pay a premium not to. Both are normal. Being surprised is what costs money.
  • Structure. Aluminium cold-form costs a multiple of PVC. A rigid jar costs a multiple of a stand-up pouch of the same fill.
  • Print. Every additional colour, foil, spot varnish or soft-touch finish is another pass on press and another reason a delivery gets rejected on colour.
  • Tooling. Cutting dies, printing plates and cylinders, blister forming tools, bespoke caps or jar moulds. One-time costs, but they sit on the critical path, and a bespoke shape is a multi-week commitment rather than a design flourish.
  • Dead stock. If you reformulate, change factory, or the registration comes back with different wording, printed stock becomes waste. Where you can, keep the volatile mandatory text on the cheapest component to rerun.

Compatibility testing, which almost nobody budgets

The pack and the product have to be tested together, not separately: ink and plasticiser migration, seal integrity at fill temperature, cap torque after transit, leak testing, and a drop test on the loaded shipper. A pack that passes on a specification sheet and fails on a truck is still a failed pack.

Settle these in week one

  • Dosage form and primary pack together, with the formulator in the room
  • Moisture, oxygen and light sensitivity of the formula, before the pack is chosen
  • Shelf-life claim and storage statement, because they determine the stability protocol and the barrier you need
  • Every market the pack will be sold into, including the ones in year two
  • Case count, shipper dimensions and pallet pattern
  • Who owns the barcodes, the artwork files and the print tooling
  • The factory, because its name is going on the pack by law

Getting the first three wrong is a reformulation. Getting the last one wrong is a reprint.

For how packaging sits against the other stages, see 45 to 90 days — and why your launch date is decided before that clock starts, and for the format decision itself, thirteen dosage forms, and how to pick the right one.

Sources

  1. Recorded interviews with Dr. Mohamed Anwar, chairman of Organix, including the "Ard al-Waqea" and "Khat al-Intag" podcasts. Quotations are translated from Arabic
  2. Al Nour News — Organix raises manufacturing standards to Class D Pharmaceutical (Aug 2026)

All articles